Received: 13 May 2022
Accepted: 7 November 2022
First Online: 5 December 2022
: This study complied with all relevant market research guidelines and legal obligations and data were collected according to European Pharmaceutical Marketing Research Association [CitationRef removed]. Ethical approval waiver was granted by Western Institutional Review Board, Inc. and Freiburger Ethik Kommission International, official independent bodies that reviewed the Disease Specific Programme™ (DSP) methodology in the United States and European Union markets. No identifiable protected health information was extracted during the course of the study. Using a checkbox, patients provided informed consent to take part in the survey. Data were collected in such a way that patients and physicians could not be identified directly.
: Not applicable.
: Naoshi Fukui acted as a paid consultant and/or speaker for Pfizer Japan Inc. and Ono Pharmaceutical Co., Ltd. Nozomi Ebata, Kanae Togo, Joseph Cappelleri and Lucy Abraham are employees of Pfizer with stock and/or stock options. Mia Berry and James Jackson are employees of Adelphi Real World who are paid consultants to Pfizer and Eli Lilly & Company in connection with this study.